| |
| |
|
| Insider
Information: |
Lyons Gary A |
| Relationship: |
|
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
506,803 |
|
|
Indirect Shares
|
387,931 |
|
|
| Direct
Value |
$17,047,060 |
|
|
|
Indirect Value
|
$53,482,716 |
|
|
| Total
Shares |
894,734 |
|
|
| Total
Value |
$70,529,776 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-05-17 |
119,047 |
2005-12-19 |
383,573 |
Premium* |
|
|
Ardea Biosciences Inc |
RDEA |
Director |
2003-11-25 |
0 |
2003-11-25 |
0 |
Premium* |
|
|
Fresh Tracks Therapeutics Ord Shs |
FRTX |
Director |
2020-12-31 |
18,762 |
2009-05-21 |
0 |
Premium* |
|
|
Poniard Pharmaceuticals |
PARD |
Director |
2011-07-11 |
206,145 |
2010-07-12 |
0 |
Premium* |
|
|
Plus Therapeutics Inc |
PSTV |
Director |
2015-05-08 |
36,849 |
2016-06-15 |
4,358 |
Premium* |
|
|
Travere Therapeutics, Inc |
TVTX |
|
2024-05-08 |
51,000 |
2014-10-08 |
0 |
Premium* |
|
|
Rigel Pharmaceuticals Inc |
RIGL |
|
2023-05-26 |
75,000 |
2021-05-19 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
114 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 5
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-12-01 |
4 |
AS |
$116.77 |
$583,837 |
D/D |
(5,000) |
203,697 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
President and CEO |
• • – |
2004-05-03 |
4 |
AS |
$62.50 |
$626,250 |
I/I |
(10,000) |
646,723 |
|
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2017-12-01 |
4 |
AS |
$72.92 |
$729,182 |
D/D |
(10,000) |
272,066 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2015-09-18 |
4 |
AS |
$54.66 |
$823,300 |
D/D |
(15,000) |
252,066 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2019-07-30 |
4 |
AS |
$92.07 |
$920,686 |
D/D |
(10,000) |
235,697 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2014-03-07 |
4 |
D |
$17.50 |
$933,293 |
D/D |
(53,331) |
304,164 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2014-03-07 |
4 |
OE |
$10.98 |
$933,300 |
D/D |
85,000 |
357,495 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2021-06-10 |
4 |
AS |
$100.27 |
$1,002,743 |
D/D |
(10,000) |
213,697 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2015-03-24 |
4 |
AS |
$41.53 |
$1,245,900 |
D/D |
(30,000) |
267,066 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2023-12-22 |
4 |
AS |
$130.04 |
$1,300,443 |
D/D |
(10,000) |
193,697 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2022-04-25 |
4 |
AS |
$92.76 |
$1,391,393 |
D/D |
(15,000) |
208,697 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2018-06-13 |
4 |
AS |
$99.24 |
$1,488,549 |
D/D |
(15,000) |
260,697 |
0 |
- |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2024-05-14 |
4 |
AS |
$135.63 |
$1,695,370 |
D/D |
(12,500) |
116,947 |
0 |
% |
|
| NBIX |
Neurocrine Biosciences In... |
Director |
– • – |
2022-10-31 |
4 |
AS |
$114.76 |
$1,721,403 |
D/D |
(15,000) |
203,697 |
0 |
% |
|
114 Records found
|
|
Page 5 of 5 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
